0001479290-18-000080.txt : 20180511
0001479290-18-000080.hdr.sgml : 20180511
20180511203052
ACCESSION NUMBER: 0001479290-18-000080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180510
FILED AS OF DATE: 20180511
DATE AS OF CHANGE: 20180511
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Russell Angus C.
CENTRAL INDEX KEY: 0001534002
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 18828476
MAIL ADDRESS:
STREET 1: C/O INTERMUNE, INC.
STREET 2: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-742-3400
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
4
1
wf-form4_152608499215478.xml
FORM 4
X0306
4
2018-05-10
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001534002
Russell Angus C.
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BOULEVARD
NEWARK
CA
94560
1
0
0
0
Common Stock
2018-05-10
4
A
0
3000
0
A
6000
D
Stock Option (Right to buy)
29.15
2018-05-10
4
A
0
6000
0
A
2028-05-09
Common Stock
6000.0
6000
D
Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.
/s/ Gordon Ho, Attorney-in-Fact
2018-05-11